CA-INSEEGO
13.12.2021 13:02:40 CET | Business Wire | Press release
Vodafone Qatar and Inseego (Nasdaq: INSG) are bringing lightning-fast internet access to home and business customers with the launch of the new 5G indoor router FX2000. Combining 5G performance with dual-band Wi-Fi 6 in a compact design, the FX2000 can connect up to 30 Wi-Fi devices, including laptops, tablets, POS systems, smartphones, televisions, smart home systems and gaming consoles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005238/en/
The Inseego Wavemaker™ 5G indoor router FX2000 is now available at Vodafone Qatar retail locations and online . Bundled with Vodafone’s 5G GigaHome Plans, the FX2000 will deliver speed, simplicity and security to users, all in a small and sleek design that fits both business and home spaces.
“Our GigaHome and business customers trust us to provide fast, reliable, secure internet access for a wide range of demanding applications,” said Diego Camberos, Chief Operating Officer, Vodafone Qatar. “The Inseego FX2000 router lets them enjoy the full power of 5G performance, whether they’re working from home, running a business, streaming movies, using AR/VR headsets, or gaming. We’re very pleased to bring this world-class solution to Qatar.”
“We’re very proud to provide Vodafone Qatar with this powerful 5G fixed wireless access solution for their customers’ home offices, business communications, and immersive multimedia entertainment experiences,” said Simon Rayne, Inseego Senior Vice President and Managing Director UK, EMEA, and Asia-Pacific. “Inseego is leading the industry with fixed wireless solutions that can deliver gigabit-plus download speeds, lag-free responsiveness and outstanding reliability.”
- The world’s smallest 5G indoor CPE – With its small footprint and low profile, the FX2000 is currently the smallest indoor customer premises equipment (CPE) on the market. It can be placed on a tabletop or desktop and moved easily when relocating to a new home or office.
- Easy setup and management – The FX2000 can be set up by anyone (no service technician needed!) in a few minutes. The Inseego Mobile smartphone app makes it easy to optimize performance and manage the FX2000 with user-friendly control settings.
- Best-in-class performance – With Inseego’s industry-leading antenna and RF technology, the FX2000 can deliver peak 5G speeds over 1 Gbps* (along with fallback to Cat 22 LTE) for fast and reliable connections with sustained high throughput and low latency for applications such as videoconferencing, streaming media, AR/VR and cloud computing. The FX2000 supports dual-band Wi-Fi 6 for up to 30 connected devices, as well as an ethernet LAN port and USB port, to connect up to 32 devices simultaneously. The ethernet LAN port can also be connected to other routing devices.
- Enterprise-grade security – Designed and developed in the U.S. with multiple layers of advanced security, the FX2000 safeguards data with advanced encryption, hacker prevention, password protection, OpenVPN, guest Wi-Fi network and more. Robust authentication protects against cyber threats and allows customers to connect with confidence to their corporate networks.
Work from anywhere – securely
Unlike slow, overcrowded, and unsecured home Wi-Fi networks, the FX2000 provides a fast, separate and secure connection to a corporate network through a carrier-managed 5G network. It provides reliable broadband for employees who don’t have dependable internet access at home.
Business-ready
Branch offices, medical offices, retail shops and restaurants all need ultra-reliable connections for their POS systems, business systems, and guest Wi-Fi networks. The FX2000 can be used for both primary internet access and as a backup solution when other internet services go down.
Trusted and secure
Designed and developed in the U.S., Inseego solutions are trusted by leading mobile operators, government agencies and enterprise customers worldwide.
To learn more about Inseego 5G products and solutions go to inseego.com . For more about the Inseego Wavemaker 5G indoor router FX2000, see https://inseego.com/products/fixed/fx2000/ . For press and analyst inquiries, please email press@inseego.com .
To find out more about Vodafone Qatar and 5G GigaNet network, please visit: https://www.vodafone.qa/en/home
* Actual speeds experienced depend upon network availability and other factors.
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry leader in smart device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency and strong security to deliver highly reliable internet access. Inseego’s mobile broadband, fixed wireless access (FWA) solutions and software platform incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6 and others) into a wide range of innovative products that provide robust connectivity indoors, outdoors and in the harshest industrial environments. Designed and developed in the USA, Inseego products and SaaS solutions build on the company’s patented technologies to provide the highest quality wireless connectivity for service provider, enterprise, and government entities worldwide. www.inseego.com #Putting5GtoWork
©2021 Inseego Corp. All rights reserved. The Inseego name and logo are registered trademarks, and the Wavemaker and Inseego Connect names are trademarks of Inseego Corp. Other Company, product or service names mentioned herein are the trademarks of their respective owners.
About Vodafone Qatar P.Q.S.C
Vodafone Qatar P.Q.S.C. ("Vodafone Qatar") provides a comprehensive range of services including voice, messaging, data, fixed communications, IoT and ICT managed services in the State of Qatar, for both consumers and businesses alike. The Company commenced commercial operations in 2009 and has 1.7 million mobile customers as of 30 September 2021. Its state-of-the-art network infrastructure is expanding to cover key locations in the country with fibre connectivity and 5G, along with an extensive digital ecosystem, which will contribute to Qatar's continued growth and prosperity. Vodafone Qatar’s vision is deeply rooted in its mission to connect today’s ideas with the technologies of tomorrow by pioneering digital innovation and becoming people’s first choice in telecom and digital services. Please visit www.vodafone.qa for more details.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005238/en/
Link:
Social Media:
https://www.facebook.com/VodafoneQatar/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom